NGD 95-1 neuropeptide Y antagonist: NRGN began a Phase I trial with NGD 95-1

Neurogen Corp. (NRGN), Branford, Conn. Product: NGD 95-1 neuropeptide Y antagonist Indication: Obesity Status: NRGN began a Phase I trial with NGD 95-1, its anti-obesity small molecule drug, in about...